A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Trial details
- Registry ID
- NCT06072781
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as avutometinib (VS-6766)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781 | VSTM | Phase 3 | Recruiting | 2028-10-15Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |